Protein Summary
Binds specifically to calcyclin in a calcium-dependent manner (By similarity). Required for midbody formation and completion of the terminal phase of cytokinesis. This gene encodes a member of the annexin family, a group of calcium-dependent phospholipid-binding proteins. Annexins have unique N-terminal domains and conserved C-terminal domains, which contain calcium-dependent phospholipid-binding sites. The encoded protein is a 56-kD antigen recognized by sera from patients with various autoimmune diseases. Several transcript variants encoding two different isoforms have been identified. [provided by RefSeq, Dec 2015]
- ENST00000265447
- ENSP00000265447
- ENSG00000122359
- ENST00000372231
- ENSP00000361305
- ENST00000422982
- ENSP00000404412
- ENST00000438331
- ENSP00000398610
- ANX11
- ALS23
- ANX11
- CAP50
- CAP-50
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 0.99 | ||
interacting protein | 0.98 | ||
kinase perturbation | 0.95 | ||
transcription factor binding site profile | 0.88 | ||
molecular function | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 141.75 (req: < 5)
Gene RIFs: 40 (req: <= 3)
Antibodies: 285 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 141.75 (req: >= 5)
Gene RIFs: 40 (req: > 3)
Antibodies: 285 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0